Lazabemide – 50 mg

Brand:
Cayman
CAS:
103878-84-8
Storage:
-20
UN-No:
Non-Hazardous - /

Monoamine oxidases, MAO-A and MAO-B, regulate the intracellular concentrations of biogenic monoamines such as 5-hydroxytryptamine and dopamine via oxidative deamination. Inhibitors of MAO-A are widely used for the therapy of affective disorders, whereas MAO-B inhibitors have clinical efficacy in the treatment of Parkinson’s disease.{21368} Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively.{21370} It is structurally similar to the MAO-B preferential substrate phenylethylamine and can be oxidized by MAO-B, forming tightly, but reversibly, bound adducts with the active site of the enzyme.{21369} The selectivity of lazabemide for MAO-B inhibition has been demonstrated in both in vitro and ex vivo conditions and it was evaluated in clinical trials for possible neuroprotective actions in the treatment of Parkinson’s disease.{21368}  

 

Available on backorder

SKU: 11640 - 50 mg Category:

Description

A selective and reversible inhibitor of MAO-B (IC50s = 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively) that is structurally similar to phenyethylamine; evaluated in clinical trials for possible neuroprotectiove actions in the treatment of Parkinson’s disease


Formal name: N-(2-aminoethyl)-5-chloro-2-pyridinecarboxamide

Synonyms:  Ro 19-6327/000

Molecular weight: 199.6

CAS: 103878-84-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease